Eculizumab for high-risk TA-TMA after stem cell transplant
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests whether eculizumab can safely help people with a serious blood vessel complication called TA-TMA after a stem cell transplant. You may be eligible if you have high-risk features and haven't improved with initial care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You had a stem cell transplant within the last year.
- You have been diagnosed with TA-TMA in the past 2 weeks, with at least 4 signs like high LDH, broken red blood cells, low platelets, low red blood cells, high blood pressure, protein in urine, or high C5b-9 levels.
- You have a high-risk form of TA-TMA, such as severe proteinuria, multiple organ problems, or high IL-10 levels.
- Your TA-TMA has not improved after trying treatments like stopping certain medications, treating infections, or managing graft-versus-host disease.
- You are not allergic to eculizumab, have not had a recent meningococcal infection, and do not have certain other serious conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medicine called iptacopan for people who have a serious blood vessel complication after a stem cell transplant (TA-TMA) that is not improving with usual treatments. The goal is to see if iptacopan can help stop the damage and improve recovery.
This study looks at people who have a blood clotting problem called TMA after a stem cell transplant from a donor. It gathers information from routine checkups to learn more about this condition.
This study tracks patients who receive a stem cell transplant from a donor to see how often they develop a blood condition called transplant-associated thrombotic microangiopathy (TA-TMA). The goal is to identify patients at higher risk and monitor them closely for this condition.
This trial looks for proteins in the blood that could help detect transplant-related blood vessel damage (called TMA) earlier, so doctors can treat it faster. It involves patients who have had a stem cell transplant from a donor.
This study looks at how two immune system proteins, interferon and complement, are involved in a rare condition called thrombotic microangiopathy (TMA) that can damage small blood vessels after a stem cell or organ transplant. Understanding these proteins may help doctors find better treatments for TMA and related complications.
This study tests a new medicine called TGD001 for people with a group of rare blood disorders called thrombotic microangiopathies (TMAs), where small blood clots form and damage organs. The goal is to see if TGD001 can help stop the clotting and improve outcomes.
Hear when a new Transplant-Associated Thrombotic Microangiopathy (TA-TMA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.